M. Melissa Hunter-Ensor, Ph.D.

M. Melissa Hunter-Ensor, Ph.D.: Attorney with Greenberg Traurig, LLP


Dr. Melissa Hunter-Ensor is Vice-Chair of Greenberg Traurig's Global Patent Prosecution Group. Melissa focuses her practice on the intellectual property and commercial needs of clients in the life science industry, encompassing pharmaceutical, biotechnology, chemical agricultural, diagnostics and medical device companies. Melissa has experience representing clients throughout the business cycle, from start-ups and universities to global pharmaceutical companies, with patent portfolio management and strategic alliances, as well as litigation and pre-litigation strategy. She also assists venture capital firms and other investors in assessing the IP risks of target investments and conducts IP patent and licensing due diligence in connection with life science technology transactions.

Before becoming a lawyer, Melissa earned a Ph.D. in neuroscience from the University of Pennsylvania and her thesis research resulted in a first author paper in Cell . She followed this accomplishment with a four-year post-doctoral fellowship at the Massachusetts Institute of Technology laboratory of Nobel laureate H. Robert Horvitz where she was a Jane Coffin Childs fellow.


•Patent portfolio management and strategic counseling
•Technology transactions and licensing
•Litigation and pre-litigation strategy

Recognition & Leadership

Awards & Accolades

•Listed, Super Lawyers magazine, Massachusetts Super Lawyers, “Rising Stars,” 2017-2018
• Massachusetts Women's Edition, Rising Stars 2018
•Listed, Managing IP Magazine's World IP Handbook and Survey, IP Stars, 2017-2018
•Listed, LMG Life Sciences, Life Science Star, 2016-2018
•Selected, Top Women of Law, Massachusetts Lawyers Weekly, 2015

Areas of Practice (4)

  • Intellectual Property & Technology
  • Life Sciences & Medical Technology
  • Patent Prosecution
  • IP Technology Licensing & Transactions

Education & Credentials

Contact Information:
617.310.6224  Phone
617.310.6001  Fax
University Attended:
Smith College, B.A., 1985; University of Pennsylvania, Ph.D., 1997
Law School Attended:
Suffolk University Law School, J.D., cum laude, 2008
Year of First Admission:
U.S. Court of Appeals for the Federal Circuit; registered to practice before U.S. Patent and Trademark Office; U.S. District Court for the District of Massachusetts; 2008, Massachusetts; Supreme Court of the United States

Professional & Community Involvement

•Board Member, Terry's Foundation for Muscular Dystrophy
•Member, Association of University Technology Managers
•Member, Public Policy Committee
•Member, Licensing Executives Society (LES)
•Member, Boston Patent Law Association
•Member, Boston Emerging Leaders Group
•Member, MIT Enterprise Forum
•Member, Life Science Circle
•Advisor, de la Femme

Birth Information:
July 13, 1963
Reported Cases:
Experience: Patent Portfolio Management and Strategic Counseling: Devised a strategy for protecting and licensing a novel nucleic acid amplification method resulting in patent grant in the U.S. and numerous international jurisdictions in under two years.; Developed a worldwide IP portfolio for a privately held company for a biologic agent that was granted an emergency exemption by the Environmental Protection Agency for use in 17 states.; Developed a world-wide IP portfolio prosecution strategy for a public company that resulted in patent protection for Alzheimer's disease, lung cancer, ovarian cancer and peripheral artery disease diagnostics.; Crafted an international strategy resulting in granted patents for a local drug delivery device that is in clinical use.; Technology Transactions and Licensing: A key member of a team assisting a Japanese pharmaceutical company with IP Iicensing due diligence that formed the basis for a multi-billion dollar acquisition of a publicly held biotechnology company.; Conducted a patent landscape analysis on behalf of multiple university clients that informed their licensing negotiations with venture capital investors resulting in the successful formation of a university-licensed start-up.; Advised an international pharmaceutical company in licensing exclusive, worldwide rights for research, development, manufacturing and commercialization of a polynucleotide-based therapeutic.; Litigation and Pre-Litigation Strategy: Advised a publicly held pharmaceutical company in evaluating whether internet sales of a small molecule pharmaceutical product were exempt from infringement under the safe harbor provided by U.S.C. 271(e)(1).; Represented the General Hospital Corporation in an inventorship dispute that resulted in summary judgment for the hospital, which was affirmed by the Court of Appeals for the Federal Circuit.; Represented a university in an inventorship dispute that involved undergraduate research.; Worked with the university's general counsel to revise the institution's Intellectual Property Policy with regard to undergraduate researchers.; The above representations were handled by Dr. Hunter-Ensor prior to her joining Greenberg Traurig, LLP.

Peer Reviews

This lawyer does not have peer reviews.

*Peer Reviews provided before April 15, 2008 are not displayed.

Boston, Massachusetts

Contact M. Melissa Hunter-Ensor, Ph.D.

Required Fields

Required Fields

By clicking on the "Submit" button, you agree to the Terms of Use, Supplemental Terms and Privacy Policy. You also consent to be contacted at the phone number you provided, including by autodials, text messages and/or pre-recorded calls, from Martindale and its affiliates and from or on behalf of attorneys you request or contact through this site. Consent is not a condition of purchase.

You should not send any sensitive or confidential information through this site. Emails sent through this site do not create an attorney-client relationship and may not be treated as privileged or confidential. The lawyer or law firm you are contacting is not required to, and may choose not to, accept you as a client. The Internet is not necessarily secure and emails sent though this site could be intercepted or read by third parties.